Health Care • Biotechnology: Pharmaceutical Preparations
$0.84 ▼ -0.03
(-3.84%)
MKT CAP: $4.2M • VOL: 32.2K
52W L $1 52W H $5
ROARABLE / RQD
D- • 43/100
PIOTROSKI
1 / 9
DRMA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$7.8M | -$12.5M | -$8.0M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$7.6M | -$12.3M | -$7.8M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$7.8M | -$11.2M | -$6.4M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$7.8M | -$11.2M | -$6.4M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $7.5M | $3.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $6.2M | $1.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR DRMA.